Cargando…

P14-04. HIV-SELECTEST EIA and rapid test: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies

Detalles Bibliográficos
Autores principales:	Khurana, S, Norris, PJ, Busch, MP, Mlisana, K, Salim, AK, Hunter, E, Golding, H
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767684/ http://dx.doi.org/10.1186/1742-4690-6-S3-P192

Ejemplares similares

Assessment of the ability DS-EIA-HIV-AB-TERM assay correctly identify long-standing and recent HIV infection
por: Zagryadskaya, YE, et al.
Publicado: (2014)

Comparative evaluation of rapid tests, HIV specific peptide EIA and Western Blot test for diagnosis of HIV-2 and HIV 1&2 infection
por: Shastri, Jayanthi, et al.
Publicado: (2012)

HIV Incidence Estimates Using the Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014
por: Simmons, Ruth, et al.
Publicado: (2016)

Comparative Performance of Electrochemiluminescence Immunoassay and EIA for HIV Screening in a Multiethnic Region of China
por: Bi, Xiaohui, et al.
Publicado: (2012)

Toxin Detection by Cell Culture Neutralization Assay [CYT] and Toxin based EIA [Tox EIA] among Recurrent Episodes of CDI Diagnosed by PCR
por: Kamboj, Mini, et al.
Publicado: (2017)

High level of HIV false positives using EIA-based algorithm in survey: Importance of confirmatory testing
por: Augusto, Ângelo do Rosário, et al.
Publicado: (2020)

New fluorimetric assay of horseradish peroxidase using sesamol as substrate and its application to EIA
por: Arakawa, Hidetoshi, et al.
Publicado: (2012)

Recalibration of the Limiting Antigen Avidity EIA to Determine Mean Duration of Recent Infection in Divergent HIV-1 Subtypes
por: Duong, Yen T., et al.
Publicado: (2015)

Environmental impact assessment (EIA) : cutting edge for the twenty-first century
por: Gilpin, Alan
Publicado: (1995)

EIA effectiveness in Vietnam: key stakeholder perceptions
por: Clarke, B.D., et al.
Publicado: (2021)

609. Development of an Aspergillus Antigen Detection EIA
por: Bridges, Nicole, et al.
Publicado: (2023)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

Expression of ORF2 protein of TTV for development of EIA system
por: Singh, Shiwani, et al.
Publicado: (2012)

P09-04. Charge changes in the alpha2-helix in the C3 region of the HIV-1 subtype C envelope mediate neutralization escape
por: Moore, PL, et al.
Publicado: (2009)

Anti-HBc IgM and anti-delta screening by EIA method.
por: Kim, J. S., et al.
Publicado: (1986)

2366. PCR Followed by Toxin EIA for the Diagnosis of C. difficile Infection
por: Zhang, Yu, et al.
Publicado: (2019)

Mean Recency Period for Estimation of HIV-1 Incidence with the BED-Capture EIA and Bio-Rad Avidity in Persons Diagnosed in the United States with Subtype B
por: Hanson, Debra L., et al.
Publicado: (2016)

S04-04 OA. HIV-specific responses induced by anti-CD40 targeting antibodies
por: Loof, N, et al.
Publicado: (2009)

P04-14. Sequential HIV-1 isolates from infected individuals reveals emergence of neutralization sensitive HIV-1 strains in the course of infection
por: Nyambi, PN, et al.
Publicado: (2009)

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
por: Brown, BK, et al.
Publicado: (2009)

P04-19. Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay
por: Peachman, K, et al.
Publicado: (2009)

P13-04. HIV positive women empowerment is equal to hiv prevalence reduction
por: Akolo, MM, et al.
Publicado: (2009)

A report on the performance of the Gilford EIA 50 automated micro-ELISA processor
por: Goodburn, R., et al.
Publicado: (1982)

An M. Boms BCG cell wall glicopeptid — EIA for antituberculosis antibodies detection
por: Romanova, R.Yu., et al.
Publicado: (1994)

OA011-04. Striking elevations in systemic and mucosal cytokine and chemokine levels in acute HIV-1 infection
por: Stacey, A, et al.
Publicado: (2009)

Diagnostic accuracy cohort study and clinical value of the Histoplasma urine antigen (ALPHA Histoplasma EIA) for disseminated histoplasmosis among HIV infected patients: A multicenter study
por: Torres-González, Pedro, et al.
Publicado: (2018)

Tip60 Degradation by Adenovirus Relieves Transcriptional Repression of Viral Transcriptional Activator EIA
por: Gupta, Ashish, et al.
Publicado: (2012)

781. C.difficile PCR+/ Toxin EIA- treat or not treat? A clinician survey
por: Nath, Sarath G, et al.
Publicado: (2020)

HIA and EIA Are Different, but Maybe Not in the Way We Thought They Were: A Bibliometric Analysis
por: Kim, Jinhee, et al.
Publicado: (2021)

Abstract papers from the Energy Informatics.Academy Conference 2022 (EI.A 2022)
Publicado: (2022)

EXM 85-04: 14/03/1985
por: Malandain, E
Publicado: (1985)

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable
por: Xu, H, et al.
Publicado: (2009)

Comparison of measles IgG enzyme immunoassays (EIA) versus plaque reduction neutralization test (PRNT) for measuring measles serostatus: a systematic review of head-to-head analyses of measles IgG EIA and PRNT
por: Lutz, Chelsea S., et al.
Publicado: (2023)

Tuning of the Hanle effect from EIT to EIA using spatially separated probe and control beams
por: Bhattarai, Mangesh, et al.
Publicado: (2018)

P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients
por: Karita, E, et al.
Publicado: (2009)

P04-46. Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
por: Fenyö, E, et al.
Publicado: (2009)

Anaemia in Acute HIV-1 Subtype C Infection
por: Mlisana, Koleka, et al.
Publicado: (2008)

CS14-04 The Development of an AIDS Mucosal Vaccine
por: Chen, Zhiwei
Publicado: (2009)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_0pqe7885shrg9fk0o7v59m6e09